These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 34205588)
1. Co-Stimulatory versus Cell Death Aspects of Agonistic CD40 Monoclonal Antibody Selicrelumab in Chronic Lymphocytic Leukemia. Delgado R; Kielbassa K; Ter Burg J; Klein C; Trumpfheller C; de Heer K; Kater AP; Eldering E Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34205588 [TBL] [Abstract][Full Text] [Related]
2. Latent sensitivity to Fas-mediated apoptosis after CD40 ligation may explain activity of CD154 gene therapy in chronic lymphocytic leukemia. Chu P; Deforce D; Pedersen IM; Kim Y; Kitada S; Reed JC; Kipps TJ Proc Natl Acad Sci U S A; 2002 Mar; 99(6):3854-9. PubMed ID: 11891278 [TBL] [Abstract][Full Text] [Related]
3. CD40 stimulation of B-cell chronic lymphocytic leukaemia cells enhances the anti-apoptotic profile, but also Bid expression and cells remain susceptible to autologous cytotoxic T-lymphocyte attack. Kater AP; Evers LM; Remmerswaal EB; Jaspers A; Oosterwijk MF; van Lier RA; van Oers MH; Eldering E Br J Haematol; 2004 Nov; 127(4):404-15. PubMed ID: 15521917 [TBL] [Abstract][Full Text] [Related]
4. CD40 triggering enhances fludarabine-induced apoptosis of chronic lymphocytic leukemia B-cells through autocrine release of tumor necrosis factor-alpha and interferon-gama and tumor necrosis factor receptor-I-II upregulation. de Totero D; Tazzari PL; Capaia M; Montera MP; Clavio M; Balleari E; Foa R; Gobbi M Haematologica; 2003 Feb; 88(2):148-58. PubMed ID: 12604404 [TBL] [Abstract][Full Text] [Related]
5. Downregulation of the CD95 receptor and defect CD40-mediated signal transduction in B-chronic lymphocytic leukemia cells. Laytragoon-Lewin N; Duhony E; Bai XF; Mellstedt H Eur J Haematol; 1998 Oct; 61(4):266-71. PubMed ID: 9820634 [TBL] [Abstract][Full Text] [Related]
6. Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells. Decker T; Schneller F; Sparwasser T; Tretter T; Lipford GB; Wagner H; Peschel C Blood; 2000 Feb; 95(3):999-1006. PubMed ID: 10648415 [TBL] [Abstract][Full Text] [Related]
7. Resistance to CD95-mediated apoptosis of CD40-activated chronic lymphocytic leukemia B cells is not related to lack of DISC molecules expression. de Totero D; Montera M; Rosso O; Clavio M; Balleari E; Foa R; Gobbi M Hematol J; 2004; 5(2):152-60. PubMed ID: 15048066 [TBL] [Abstract][Full Text] [Related]
12. Role of the CD40 and CD95 (APO-1/Fas) antigens in the apoptosis of human B-cell malignancies. Wang D; Freeman GJ; Levine H; Ritz J; Robertson MJ Br J Haematol; 1997 May; 97(2):409-17. PubMed ID: 9163608 [TBL] [Abstract][Full Text] [Related]
13. CD40 stimulation sensitizes CLL cells to lysosomal cell death induction by type II anti-CD20 mAb GA101. Jak M; van Bochove GG; Reits EA; Kallemeijn WW; Tromp JM; Umana P; Klein C; van Lier RA; van Oers MH; Eldering E Blood; 2011 Nov; 118(19):5178-88. PubMed ID: 21948297 [TBL] [Abstract][Full Text] [Related]
14. Ibrutinib sensitizes CLL cells to venetoclax by interrupting TLR9-induced CD40 upregulation and protein translation. Kielbassa K; Haselager MV; Bax DJC; van Driel BF; Dubois J; Levin MD; Kersting S; Svanberg R; Niemann CU; Kater AP; Eldering E Leukemia; 2023 Jun; 37(6):1268-1276. PubMed ID: 37100883 [TBL] [Abstract][Full Text] [Related]
15. CD154 induces p73 to overcome the resistance to apoptosis of chronic lymphocytic leukemia cells lacking functional p53. Dicker F; Kater AP; Prada CE; Fukuda T; Castro JE; Sun G; Wang JY; Kipps TJ Blood; 2006 Nov; 108(10):3450-7. PubMed ID: 16741250 [TBL] [Abstract][Full Text] [Related]
16. Modulation of NF-kappa B activity and apoptosis in chronic lymphocytic leukemia B cells. Furman RR; Asgary Z; Mascarenhas JO; Liou HC; Schattner EJ J Immunol; 2000 Feb; 164(4):2200-6. PubMed ID: 10657675 [TBL] [Abstract][Full Text] [Related]
17. c-Abl kinase inhibitors overcome CD40-mediated drug resistance in CLL: implications for therapeutic targeting of chemoresistant niches. Hallaert DY; Jaspers A; van Noesel CJ; van Oers MH; Kater AP; Eldering E Blood; 2008 Dec; 112(13):5141-9. PubMed ID: 18796631 [TBL] [Abstract][Full Text] [Related]